News

Imaging Endpoints has launched a whole new look online. Visit our new website at https://imagingendpoints.com/ and learn about all of our exciting and comprehensive novel imaging services.

Imaging Endpoints’ novel radiomic imaging technology has identified a potentially useful biomarker to non-invasively evaluate DKK1 expression according to updated clinical data presented by Leap Therapeutics Inc. The findings come from a recently completed Phase 1/2 clinical trial of DKN-01…   Read More

Imaging Endpoints announced today that the Company is well prepared for the business implications of the COVID-19 pandemic. Imaging Endpoints (IE) has implemented a Wellness Policy with strict protections for its workforce and has moved many of its staff to…   Read More

Imaging Endpoints announced today that they are exploring ways to offer their centralized, global imaging capabilities and radiomics technology to help improve diagnosis and management of Coronavirus on a global scale. The Company’s unique cloud-based system enables it to receive…   Read More

It was a great week for Imaging Endpoints at the Immuno-Oncology 360 conference in New York City. Thanks to everyone that stopped by to talk and learn about our novel imaging solutions. If you want to learn more about us,…   Read More

Imaging Endpoints is a founding sponsor of Immuno-Oncology 360 (IO360) and is proud to once again be a lead sponsor for the IO360 conference on February 26-28 in New York City. In addition to being in the exhibition hall with…   Read More

Imaging Endpoints is perhaps the most dynamic and fastest-growing company in the imaging CRO industry. We value our team members and offer a host of benefits designed to develop a positive work environment. We are actively recruiting for a variety…   Read More

Imaging Endpoints’ Chief Medical Officer Ron Korn will be presenting “New Imaging Technologies for Evaluation of Immune Response” at the 6th Annual Immuno-Oncology 360 conference Feb. 26-28 in New York City. To schedule a visit with our team on-site, contact…   Read More

We leverage the analysis of FDG-PET images to expand eligibility in clinical trials by providing a means to evaluate disease in patients who are otherwise non-assessable by RECIST. As an example, bone-only disease can be a leading reason for classification…   Read More

Virginia O’Malley, Imaging Endpoints’ Vice President and General Counsel was recognized as a finalist for the 2020 Arizona Corporate Counsel Award for the Technology Company category at a recent ceremony in Scottsdale. The award recognition was presented by AzBusiness magazine…   Read More